-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisaftoclax in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisaftoclax in Hairy Cell Leukemia Drug Details: Lisaftoclax (APG -2575)...
-
Product Insights
Bronchiectasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bronchiectasis Clinical Trial Report Overview A total of 394 Bronchiectasis clinical trials were conducted as of March 2024. The Bronchiectasis clinical trial report provides a comprehensive understanding of the Bronchiectasis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab Vedotin in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Solid Tumor Drug Details: Donafenib tosylate (Zepsun)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CHF-6333 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHF-6333 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CHF-6333 in Cystic Fibrosis Drug Details: CHF-6333 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CHF-6333 in Bronchiectasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHF-6333 in Bronchiectasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CHF-6333 in Bronchiectasis Drug Details: CHF-6333 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Birch Triterpenes in Radiodermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Birch Triterpenes in Radiodermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Birch Triterpenes in Radiodermatitis Drug Details: Birch bark extract (Oleogel-S10, Filsuvez, Episalvan)...
-
Product Insights
Chronic Bronchitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Bronchitis - Drugs In Development, 2023’, provides an overview of the Chronic Bronchitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...